<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="100017"><DrugName>Sulfolase CR</DrugName><DrugNamesKey><Name id="43106284">Sulfolase CR</Name></DrugNamesKey><DrugSynonyms><Name><Value>acebrophylline</Value></Name><Name><Value>HDDO-1601</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>HOB-051</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Sulfolase CR</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>179118-73-1</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="22606">Hyundai Pharmaceutical</CompanyOriginator><CompaniesPrimary><Company id="22606">Hyundai Pharmaceutical</Company></CompaniesPrimary><CrossReferences><SourceEntity id="22606" type="Company"><TargetEntity id="4295881051" type="organizationId">Hyundai Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="50" type="ciIndication"><TargetEntity id="10006451" type="MEDDRA"></TargetEntity><TargetEntity id="D001991" type="MeSH"></TargetEntity><TargetEntity id="-913454587" type="omicsDisease"></TargetEntity><TargetEntity id="278" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Bronchitis - South Korea - Dec-2017</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="50">Bronchitis</Indication></IndicationsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="595">Tablet formulation</Technology><Technology id="641">Controlled release formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="585">Oral formulation</Technology></Technologies><LastModificationDate>2019-04-05T16:45:08.000Z</LastModificationDate><ChangeDateLast>2017-08-07T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-26T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="22606" linkType="Company"&gt;Hyundai Pharma&lt;/ulink&gt; has developed and launched Sulfolase CR (HDDO-1601, previously HOB-051), a controlled release tablet formulation of acebrophylline, for the treatment of bronchitis [&lt;ulink linkID="1746190" linkType="Reference"&gt;1746190&lt;/ulink&gt;], [&lt;ulink linkID="1710896" linkType="Reference"&gt;1710896&lt;/ulink&gt;]. In 2017, the  agent was made available  [&lt;ulink linkID="2138536" linkType="Reference"&gt;2138536&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In February 2017, the formulation was approved in Korea [&lt;ulink linkID="1909192" linkType="Reference"&gt;1909192&lt;/ulink&gt;]. At that time, launch was planned for the first half of the year [&lt;ulink linkID="1905186" linkType="Reference"&gt;1905186&lt;/ulink&gt;]. In July 2017, the plan was moved to 2H17 [&lt;ulink linkID="1946873" linkType="Reference"&gt;1946873&lt;/ulink&gt;]. In 2017, the  agent was made available  [&lt;ulink linkID="2138536" linkType="Reference"&gt;2138536&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In October 2015, phase III development was underway [&lt;ulink linkID="1746190" linkType="Reference"&gt;1746190&lt;/ulink&gt;]. By February 2017, launch was planned for the first half of the year [&lt;ulink linkID="1905186" linkType="Reference"&gt;1905186&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2015, phase I development had been completed  [&lt;ulink linkID="1746190" linkType="Reference"&gt;1746190&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="50">Bronchitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-31T00:00:00.000Z</StatusDate><Source id="2138536" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="50">Bronchitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-10-15T00:00:00.000Z</StatusDate><Source id="1746190" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="50">Bronchitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-10-15T00:00:00.000Z</StatusDate><Source id="1746190" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="50">Bronchitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-02-24T00:00:00.000Z</StatusDate><Source id="1909192" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2138536" linkType="reference" linkID="2138536"&gt;2138536&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>Cn1c(=O)n(c(=O)c2c1ncn2CC(=O)O)C.c1c(c(c(cc1Br)Br)N)CN[C@H]2CC[C@@H](CC2)O</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="2660191" number="WO-2014003371" title="Immediate-release and sustained-release pharmaceutical composition comprising acebrophylline"></PatentFamily><PatentFamily id="2916541" number="WO-2015099365" title="Sustained-release pharmaceutical composition containing acebrophylline and hydrophillic sustained-release agent"></PatentFamily><PatentFamily id="2916542" number="WO-2015099364" title="Sustained-release pharmaceutical composition containing acebrophylline and hydrophobic sustained-release agent"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hyundai Pharmaceutical" id="22606"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>